Abstract
BACKGROUND AND OBJECTIVE: Cancer cells accumulate high concentrations of reactive oxygen species as a result of their faster and uninhibited metabolic activity. Cancer chemotherapeutic agents release an excess of severe adverse reactions as a result of targeting normal cells. This demands an improvement in targeted drug-delivery systems to selectively discharge anticancer drugs in the vicinity of such highly metabolically and mitotically active cells. MATERIALS AND METHODS: Here, magnetic nanoparticles were synthesized by a traditional co-precipitation technique. Fe(3)O(4)@OA-CS-5-FLU-NPs were synthesized by an easy and rapid in situ loading method. The proposed Fe(3)O(4)@OA-CS-5-FLU-NPs were productively prepared as well as characterized by various spectroscopic and microscopic studies. RESULTS: The targeted drug release profile of the Fe(3)O(4)@OA-CS-5-FLU-NPs was studied in the presence of ROS including H(2)O(2) and pH induction. The released product, Fe(3)O(4)@OA-CS-5-FLU-NP, exhibited desirable levels of cytotoxicity and demonstrated morphological changes and inhibition of colony formation for A549 and HeLa S3 cancer cells. The IC50 values at 24 hours were 12.9 and 23 μg/mL, respectively. CONCLUSION: In summary, results from the MTT assay, fluorescence staining as well as colony formation assays, revealed that the Fe(3)O(4)@OA-CS-5-FLU-NPs were active and safe for anticancer biomedical applications. In summary, the present investigation provides a powerful nanostructured based system for improved cancer theranostics that should be further studied.